163 related articles for article (PubMed ID: 23988443)
1. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging.
Pritchard S; Glover M; Guthrie G; Brum J; Ramsey D; Kappler G; Thomas P; Stuart S; Hull D; Gowland P
Pulm Pharmacol Ther; 2014 Feb; 27(1):121-6. PubMed ID: 23988443
[TBL] [Abstract][Full Text] [Related]
2. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours.
Druce HM; Ramsey DL; Karnati S; Carr AN
Rhinology; 2018 Dec; 56(4):343-350. PubMed ID: 29785414
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Effect of Sinex® (0.05% Oxymetazoline) Nasal Spray on Reduction of Nasal Congestion Using Computational Fluid Dynamics.
Kishore A; Blake L; Wang C; Ba S; Gross G
J Biomech Eng; 2015 Aug; 137(8):081011. PubMed ID: 26065640
[TBL] [Abstract][Full Text] [Related]
4. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
[TBL] [Abstract][Full Text] [Related]
5. How Does Oxymetazoline Change Nasal Aerodynamics and Symptomatology in Patients with Turbinate Hypertrophy?
Root ZT; Lepley TJ; Wu Z; Chapman RJ; Schneller AR; Formanek VL; Kelly KM; Otto BA; Zhao K
Laryngoscope; 2024 Mar; 134(3):1100-1106. PubMed ID: 37589314
[TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis.
Meltzer EO; Bernstein DI; Prenner BM; Berger WE; Shekar T; Teper AA
Am J Rhinol Allergy; 2013; 27(2):102-8. PubMed ID: 23562197
[TBL] [Abstract][Full Text] [Related]
7. Effects of oxymetazoline on nasal flow and maximum aerobic exercise performance in patients with inferior turbinate hypertrophy.
Gómez-Hervás J; García-Valdecasas Bernal J; Fernández-Prada M; Palomeque-Vera JM; García-Ramos A; Fernández-Castanys BF
Laryngoscope; 2015 Jun; 125(6):1301-6. PubMed ID: 25546052
[TBL] [Abstract][Full Text] [Related]
8. The effect of inferior turbinate hypertrophy on nasal spray distribution to the middle meatus.
Dowley AC; Homer JJ
Clin Otolaryngol Allied Sci; 2001 Dec; 26(6):488-90. PubMed ID: 11843929
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of the efficacy of combined nasal topical drug and topical decongestants in the treatment of acute rhinosinusitis].
Shakhova EG
Vestn Otorinolaringol; 2020; 85(4):46-50. PubMed ID: 32885637
[TBL] [Abstract][Full Text] [Related]
10. Acute coronary syndrome after nasal spray of oxymetazoline.
Montastruc F; Montastruc G; Taudou MJ; Olivier-Abbal P; Montastruc JL; Bondon-Guitton E
Chest; 2014 Dec; 146(6):e214-e215. PubMed ID: 25451367
[No Abstract] [Full Text] [Related]
11. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects.
Eskiizmir G; Hirçin Z; Ozyurt B; Unlü H
Eur J Clin Pharmacol; 2011 Jan; 67(1):19-23. PubMed ID: 21069518
[TBL] [Abstract][Full Text] [Related]
12. Effects of early postoperative nasal decongestant on symptom relief after septoplasty.
Dağli E; Ocak E; Mirici E; Kaya M; Acar A
Int Forum Allergy Rhinol; 2018 Dec; 8(12):1476-1480. PubMed ID: 29999597
[TBL] [Abstract][Full Text] [Related]
13. Isolated Topical Decongestion of the Nasal Septum and Swell Body Is Effective in Improving Nasal Airflow.
Wong E; Deboever N; Chong J; Sritharan N; Singh N
Am J Rhinol Allergy; 2020 May; 34(3):417-421. PubMed ID: 32008353
[No Abstract] [Full Text] [Related]
14. Oxymetazoline nasal spray.
Graf P
Laryngoscope; 1998 Aug; 108(8 Pt 1):1255. PubMed ID: 9707257
[No Abstract] [Full Text] [Related]
15. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.
Graf P; Hallén H
ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748
[TBL] [Abstract][Full Text] [Related]
16. Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers.
Hallén H; Graf P
Clin Exp Allergy; 1995 May; 25(5):401-5. PubMed ID: 7553242
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion.
Morris S; Eccles R; Martez SJ; Riker DK; Witek TJ
Am J Rhinol; 1997; 11(2):109-15. PubMed ID: 9129752
[TBL] [Abstract][Full Text] [Related]
18. Prevention of middle ear barotrauma with oxymetazoline/fluticasone treatment.
Millan SB; Hontz-Geisinger CA; Rooks BJ; Wahl AM; Covington DB
Undersea Hyperb Med; 2021; 48(2):149-152. PubMed ID: 33975404
[TBL] [Abstract][Full Text] [Related]
19. Double-masked, randomized, placebo-controlled study to evaluate the efficacy and tolerability of intranasal K305 (3% tetracaine plus 0.05% oxymetazoline) in anesthetizing maxillary teeth.
Hersh EV; Pinto A; Saraghi M; Saleh N; Pulaski L; Gordon SM; Barnes D; Kaplowitz G; Bloom I; Sabti M; Moore PA; Lee S; Meharry M; He DY; Li Y
J Am Dent Assoc; 2016 Apr; 147(4):278-87. PubMed ID: 26822100
[TBL] [Abstract][Full Text] [Related]
20. Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.
Neighbors CL; Salvador CF; Zhu B; Camacho M; Tsai P
J Laryngol Otol; 2022 Jan; 136(1):8-16. PubMed ID: 34702392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
